Front Page News

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

January 29, 2025
Posted in , ,

  “With the strength of our Phase 3 data as the foundation of our submission, we look forward to continuing to work closely with the […]

Read More ›

Biogen Announces that FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

January 23, 2025
Posted in ,

“We are committed to supporting individuals with SMA and their families by advancing research that aims to answer critical questions for the community.” Today, Biogen […]

Read More ›

All 2025 Walk-n-Roll Events Are Open

January 13, 2025
Posted in , ,

Cure SMA warmly invites you to join us at one of our 2025 Walk-n-Roll events-where community meets impact! This year, for the first time, you […]

Read More ›

Cure SMA Caregiving Priority Signed into Law

January 6, 2025
Posted in , ,

On January 4th, 2025, President Biden signed the Think Differently Database Act (H.R. 670) into law, marking a significant legislative victory for the SMA community. […]

Read More ›

Novartis Intrathecal Gene Therapy Onasemnogene Abeparvovec Phase III Study Meets Primary Endpoint in Children and Young Adults with SMA

December 30, 2024
Posted in , , ,

Novartis today announced positive topline results from the Phase III STEER study. This pivotal study assessed the efficacy and safety of investigational intrathecal onasemnogene abeparvovec […]

Read More ›

Cure SMA Advocacy Highlights of 2024

December 20, 2024
Posted in ,

As 2024 draws to a close, Cure SMA reflects on an extraordinary year of advocacy milestones that have advanced the priorities of individuals with spinal […]

Read More ›

Cure SMA Celebrates New DOT Rule for Accessible Air Travel

December 17, 2024
Posted in , ,

Cure SMA is thrilled to share a major win for the SMA community: the U.S. Department of Transportation (DOT) has finalized its rule on ensuring […]

Read More ›

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy

November 25, 2024
Posted in , ,

In the RESILIENT SMA study, Biohaven announced today that taldefgrobep alpha showed clinically meaningful improvements in motor function at all time points on the Motor […]

Read More ›

SMA Community Advocacy Wins and Champions Celebrated at Cure SMA Event

November 20, 2024
Posted in , ,

Individuals with spinal muscular atrophy (SMA) and their families recognized congressional champions and celebrated advocacy progress at Cure SMA’s Hope on the Hill event. U.S. […]

Read More ›

Celebrate 40 Years of Impact – Join Us in Making a Difference!

November 19, 2024
Posted in ,

Thank you for being an essential part of this journey and for believing in our mission. As we mark 40 years of dedicated service to […]

Read More ›
Scroll to Top